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SUMMARY 
 
 
During the last decades, the clinical and research interest in atherosclerosis has been 
mostly focused on coronary arteries. After the publications of the European Society 
Guidelines and AHA/ACC Guidelines on Peripheral artery diseases, and of the Registry 
REduction in Atherothrombosis for Continued Health Registry (REACH), there has been an 
increased interest in atherosclerosis of the lower extremity arteries and its presence in 
multi-focal disease. However, awareness in the general population and the medical 
community of non-coronary artery diseases, and of its major prognostic implications 
remain relatively low. The aim of this general review stemming out of an ESC Working 
Group on Peripheral Circulation meeting in 2011 is to enhance awareness of this complex 
disease highlighting the importance of the involvement of atherosclerosis at different levels  
with respect to clinical presentation, diagnosis, and co-existence of the disease in the 
distinct arterial territories. We also emphasize the need of an interdisciplinary approach to 
face the broad and complex spectrum of multi-focal disease, and try to propose a series of 
tentative recommendations and measures to be implemented in non-coronary 
atherosclerosis. 
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Introduction 
 
There is an increased interest among the medical community for non-coronary 
atherosclerosis.  
The most important recent initiatives in this field have been the new ESC Guidelines on the 
diagnosis and treatment of peripheral artery diseases (1), the ACC/AHA Practice 
Guidelines in management of patients with peripheral artery disease (2,3), the Trans-
Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC 
I and II) (4,5), which all have established important educational, clinical, and research goals 
for the near future. 
The pivotal results of several epidemiological studies -among others- the Basel- , and the 
Ankle-Brachial Index Collaboration study (6,7) have also highlighted this interest, with the 
former demonstrating as early as the 60s the poor prognosis of patients with lower extremity 
artery disease (LEAD). More recently, the GetABI and the Registry Reduction in 
Atherothrombosis for Continued Health Registry (REACH)(8,9) have highlighted the role of 
atherosclerosis as a systemic disease with manifestations in multiple vascular beds, and 
indicated that these patients have a poorer prognosis than patients with just one territory 
affected (9) (Figure 1). The ability by a simple diagnostic tool as the measurement of the 
ankle-brachial index (ABI), a surrogate and objective equivalent of the presence of lower 
extremity artery disease, to anticipate overall cardiovascular prognosis and apply prevention 
strategies has increased the attention for this field.(8,10,11,12) (Figure 2) Cardiologists in 
fact – as elegantly demonstrated by the initial career as specialist in vascular medicine of 
Andreas Gruentzig and his invention of angioplasty(13) - have always been aware of the 
need of a multi-focal diagnostic and therapeutic approach because atherosclerosis has a 
common pathogenesis, and simultaneously affects multiple circulatory regions. 
 
This review has been conceived following an ESC Working Group on Peripheral Circulation 
meeting held in Zürich in 2011 convening 20 cardiovascular specialists in peripheral 
circulation and atherosclerosis together with leading European and American cardiologists 
who considered appropriate, two years after publication of the ESC guidelines, to 
reinforce this relevant problem since its knowledge in cardiology community tends to be 
low. It focuses the attention on atherosclerosis affecting the different non-coronary arterial 
territories, from the upper limbs arteries, the extra-cranial carotid through the thoracic and 
abdominal aorta, the mesenteric, renal and lower limbs arteries, and emphasize the growing 
and often unrecognized burden of vascular disease. Special attention is given to the issue 
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of multifocal atherosclerosis, and the need for an interdisciplinary management. Given the 
vast extension of the topic, all facets of vascular diseases cannot be covered in detail, and 
some aspects go beyond the scope of the paper, i.e. therapeutic strategies, and will not be 
covered in this review. Finally practical suggestions for clinicians and policy makers to 
increase awareness on this important item, also highlighting some areas of uncertainties in 
this field, are proposed. 
 
Upper extremity arteries 
 
In contrast to many other territories, overt atherosclerosis of the upper limb arteries, 
including the case for the thoracic artery is relatively rare since 3 to 4% of the general public 
have a subclavian stenosis and 15 to 20% of patients with LEAD have it.(14) Conversely, it 
is intriguing to see how the upper extremity arteries (i.e. the brachial arteries) are the more 
convenient territory to assess non-invasively the endothelial dysfunction, one powerful early 
indicator of subclinical atherosclerosis. Endothelial dysfunction assessed by ultrasound 
measurement of the brachial artery flow-mediated dilation (FMD) after reactive hyperaemia 
or cold pressor test may provide prognostic information even in the absence of overt 
atherosclerosis, anticipating progression of the atherosclerotic lesions in patients with 
coronary artery disease, and in patients with lower extremity artery disease.(15) 
Measurement of endothelial function has been of paramount importance for the 
understanding of pathophysiology of early and late manifestations of atherosclerosis and its 
complications, for determining the importance of traditional and emerging risk factors of 
atherosclerosis as well as for the comprehension of the mechanisms of action of several 
drug families and lifestyle changes crucial for the prevention as well as treatment of 
atherosclerosis i.e. ACE inhibitors, and statins. A low brachial artery FMD is an independent 
predictor of cardiovascular risk.(16) Overall, the clinical relevance of upper limb 
atherosclerosis, and the use of FMD in the clinical arena remain relatively low, since the 
latter- in spite of its valid proof of concept- has not reached sufficient clinical utility. 
 
Carotid arteries 
 
The relevance of extra-cranial cerebral artery atherosclerosis is two-fold. From a clinical 
standpoint, carotid atherosclerosis is responsible for about 25% of strokes with major 
impact on disability of the growing older population.(17-19) From a clinical research 
standpoint, carotid atherosclerosis represents an extraordinary window to study in vivo early 
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and late manifestations of atherosclerosis.(20,21) The earliest visible manifestation of 
carotid artery disease is the thickening of the intima-media which is detectable with high-
resolution B-mode carotid ultrasonography (Duplex US) (22), a marker of early subclinical 
atherosclerosis which correlates with incident vascular outcomes, i.e. stroke and coronary 
heart disease (CHD). A recent meta-analysis by Lorenz et al. showed the strong predictive 
value of carotid intima-media thickness for the occurrence of cardiovascular events.(20) The 
morphological presentation of atherosclerotic plaques at the level of carotid arteries with a 
lipid core and fibrous cap is similar but not exactly the same than those found in other 
vascular areas.(23,24) Carotid atherosclerotic plaques are associated with embolization of 
superimposed thrombotic material (2,4,24,25), a phenomenon which is clinically relatively 
less relevant at the level of coronary arteries or lower limbs arteries.(1-5) It has been 
assumed that the risk of embolization or complications of carotid plaques increases in 
parallel with the degree of obstruction although the complexity of the plaque probably plays 
an even more important role.(25) The annual risk of stroke in patients with asymptomatic 
carotid stenosis (between 50% and 99%) is 1.0% to 3.3% with the higher incidence in those 
with the more severe stenosis and more rapid progression of stenosis.(2,4,25) Patients with 
symptomatic carotid artery stenosis with previous stroke have an annual recurrent stroke 
risk of between 10%- 43%.(23,25). However, it should be emphasized that most of these 
studies (22,23) have been performed before the widespread use of statins, which may 
induce stabilization or reduction in carotid atherosclerotic plaque.(2,26) Duplex US is the 
standard tool in clinical practice for detection and estimates the degree of severity of carotid 
atherosclerosis.(27) Duplex US allows to estimate not only the degree of stenosis but also 
the extension and complexity of the plaque lesion; echogenicity detected by Duplex US 
ultrasound has been proposed to identify lesions at higher risk of spontaneous complication 
or following invasive treatment (i.e. carotid surgery or stenting).(28) Contrast-enhanced 
Duplex US is another emerging application of ultrasound imaging which may allow the 
identification of intra-plaque neovascularisation, a further potential predictor of plaque 
vulnerability.(29) 
Spiral CT, and particularly MRI plaque imaging may add important information on plaques 
composition and vulnerability-detecting plaque rupture, intra-plaque haemorrhage, and the 
presence of thrombus.(21,31-33) Recently PET/CT-Scan and hybrid techniques prototypes 
using PET/CT and MRI seem to be promising research tools for identifying inflammatory 
component of atherosclerotic plaques.(33). However, so far the use of these techniques is 
proposed only to investigational purpose and are not used clinically. 
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Thoracic and abdominal aorta 
 
The pathology of the aorta has several peculiar aspects. Atherosclerotic involvement of the 
thoracic ascending aorta and of the aortic arch has been recognized as a significant source 
of “spontaneous” cerebral and peripheral thromboembolism and may represent a 
dangerous source of atherothrombotic embolism during diagnostic and invasive procedures 
(PCI, on-pump cardiac surgery).(34) Transesophageal echocardiography is one of the most 
powerful tools to detect mobile and complex plaques at the level of the aortic arch and of 
the descending aorta.(34,35) 
 
A clinically distinct feature is the athero-embolic syndrome associated with severe aortic 
atherosclerosis and embolization from ulcerated plaques. Hallmark of this syndrome are 
renal insufficiency, skin lesions, blue toe(s), caused by micro-emboli associated with 
transient eosinophilia.(36) It can occur spontaneously, but frequently results from arterial 
manipulation, such as catheter intervention and aortotomy.(37) Prognosis is poor with 1-
year mortality rates between 60-81% although this high mortality may reflect selection bias 
due to the fact that these figures derive from autopsy studies. Over 70% of patients with 
atheroembolic syndrome present renal function impairment and over 40% of these patients 
end-up with severe renal failure needing dialysis.(36,37)  
Aortic aneurysms have been traditionally considered a special form of atherosclerosis, 
because this disorder is almost always associated with severe atherosclerotic damage of 
the aortic wall, and because it shares many of the same risk factors as obstructive 
atherosclerosis. However, this conventional view has been challenged in recent years: 
basic and clinical research studies indicate that aneurysms arise through pathogenic 
mechanisms that are distinct from those responsible for athero-occlusive disease. (38,39) 
 
Renal arteries 
 
Haemodynamically significant renal artery stenosis (RAS) is associated with hypo-perfusion 
of the renal parenchyma which induces a series of (patho)-physiological responses, 
including up-regulation of the renin-angiotensin-aldosterone system followed by fluid 
retention, reduced natriuresis , and vasoconstriction which may end-up with perpetuation of 
arterial hypertension , renal fibrosis and renal function impairment (40,41). The recent 
refinement and increasing use of diagnostic procedures such as Duplex US ultrasound (42), 
angio-CT and magnetic resonance(43) in the older population with diffuse atherosclerosis 
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undergoing invasive diagnostic procedures (i.e. coronary angiography) have changed the 
spectrum of clinical presentation of RAS. Cardiologists face relatively frequently the 
management of patients with multi-morbid poly-vascular patients with uni- (or bilateral) 
atherosclerotic obstructive disease of the renal arteries. These patients may present with 
renal with resistant arterial hypertension, renal function deterioration, “flash” pulmonary 
edema and unstable angina.(44)  
Mesenteric artery 
 
The prevalence of acute and chronic mesenteric ischemia is low, but its clinical relevance is 
high since ischemia may be often fatal particularly in cases of acute presentation.(1-5) 
Mesenteric ischemia may be caused by atherosclerosis, arterial emboli, or thrombosis as 
well as several other rare pathologies affecting the mesenteric arteries (fibro muscular 
dysplasia, arterial infection, aneurysms or dissections). Acute mesenteric ischemia is often a 
result of cardio-embolic events or due to embolization following endovascular procedures. 
Other causes are arterial thrombosis based on a pre-existent stenotic lesion, acute aortic 
dissection or hypercoagulability states. Patients with acute mesenteric ischemia often 
present with abdominal pain out of proportion to physical findings associated with 
leukocytosis and lactic acidosis, and have frequently a history of cardiovascular disease or a 
recent history of cardiovascular intervention.(2,45) Computer tomography is the diagnostic 
tool to identify thrombosis of the proximal intestinal arteries and its consequences (intestinal 
wall thickening, distension, abdominal fluid or perforation). Chronic intestinal ischaemia 
affects predominantly women. Patients often present with post-prandial abdominal pain 
frequently associated with weight loss although the absence of the typical postprandial 
discomfort is not infrequent, making this diagnosis very challenging. (45) While Duplex US 
is often the first row imaging method, CT (and/or MRI) are the most adequate investigations 
to detect the affected vessels causing ischemia and its consequences. The sensitivity and 
specificity for detection of mesenteric ischaemia with newer multidetector CT and magnetic 
are for both above 90%. (46,47)  
 
Lower extremity arteries 
 
One of the most recently re-discovered aspects of non-coronary atherosclerosis is the major 
prognostic impact of the presence of a symptomatic or asymptomatic atherosclerotic 
involvement of the peripheral arteries of the lower limbs (LEAD).(1-5,8,48,49) The 
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prevalence of LEAD is high especially, in subjects over the age of 65 (Fig 3).The life 
expectancy of a patient with severe claudication is less than 80% at 5 years follow-up, and 
an additional 20% of patients suffer of non-fatal cardiovascular events. (5,49) Patients with 
more moderate symptoms or asymptomatic lower extremity artery disease are also at 
significant higher risk to die because of cardio- or cerebrovascular complications.(1-
5,8,48,49) (Fig 1) In spite of this poor survival prognosis, patients with LEAD have received 
until recently scant public attention, half of claudicants being not recognized as such.(1-
5,9,11,50,51) Once diagnosed, patients with LEAD have significantly less chance of 
receiving appropriate risk factor modification, statins, and antithrombotic treatment than 
patients with coronary or cerebrovascular disease.(9,11,51,52) 
Awareness of this condition should be promoted by the use of simple diagnostic tools such 
as measurement of the ABI, in order to detect a larger population of high-risk patients who 
should receive appropriate cardiovascular treatment.(1-5,9,11,52) The poor general 
prognosis of these patients contrasts with the relatively benign course of the local disease, 
only 25% of patients experience symptomatic deterioration, and 2 to 6% eventually lose the 
involved leg within 5 years.(1-5) 
Critical limb ischemia (CLI) deserves a special place in the spectrum of LEAD since it is a 
hallmark of dismal prognosis in terms of survival (up to 45% mortality within 1 year) and limb 
loss.(53) It is clinically defined by the presence of rest pain or gangrene associated with 
chronic ischemia, and is usually associated with an ankle pressure ≤ 50 mmHg. It may 
develop slowly or occur with acute onset of symptoms in patients following distal athero-
embolisation or in patients with multi-segmental atherothrombosis.(1-5) It should be clearly 
differentiated from acute limb ischemia, although the latter is also associated with risk of 
amputation: it follows acute arterial embolism and is accompanied by acute onset of 
symptoms with an obvious embolic source (atrial fibrillation, left ventricular aneurysm, 
atheromatous plaque in the aorta, or mural thrombus of arterial aneurysm), absence of 
previous claudication, and the presence of normal arterial pulses and Doppler systolic blood 
pressures in the contralateral extremity.(1-5,53) 
 
From the clinical research standpoint, atherosclerosis of the lower extremities still remains 
an important model to study “in vivo” pathophysiology of atherosclerosis such as the study of 
arterial remodelling (54,55) and new treatment strategies as it was the case for angioplasty 
which was first introduced by A. Gruentzig to treat non coronary atherosclerotic obstructions 
at the level of the lower limb arteries before being applied to the coronary arteries.(13) 
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A further example of how peripheral vascular medicine may be relevant to explore new 
cardiovascular revascularization strategies is angiogenesis. Intensive research in this field 
undertaken by J. Isner, another cardiologist interested in peripheral artery disease, allowed 
new insight into the complex issue of CLI, microcirculation and potential treatment modalities 
which have been relevant also for other territories (i.e. myocardium).(56, 57) Through the 
emphasis on the importance of a global view of multisite atherosclerosis, and a close 
contact among internationalists in distinct arterial fields, there is a steady increasing mutual 
influence between coronary and non-coronary vascular specialists. 
 
Multi-focal atherosclerosis (Table 1 and 2)   
 
The REACH registry has clearly confirmed that the presence of multifocal atherosclerosis 
has a major clinical and prognostic impact (Figure 1-2) (1-5,9). The co-coexistence of 
coronary artery disease plays obviously a major prognostic role in terms of mortality (1,6). 
Apart from the deemed spontaneous prognosis this may be important in those patients 
scheduled and undergoing vascular revascularization procedures, although the conclusions 
of a recent multicentre trial in patients scheduled for major vascular interventions did not 
show a significant benefit in patients undergoing preoperative coronary evaluation and 
revascularization.(58)  
The cause of the different prevalence of atherosclerosis at the level of distinct territories is 
complex. Loco-regional hemodynamic and rheological factors as a turbulent flow at 
bifurcations or side branches are also important mechanisms predisposing and favouring the 
progression of atherosclerotic lesions.(2,4) The distribution, predominance and co-existence 
of atherosclerosis at different localizations of the arterial tree, remain however frequently 
elusive although some clues of distribution emerge from epidemiological series. Genetic, 
traditional, and/or emerging risk factors, (inflammatory markers), environmental and socio-
economic factors all may play an important role.(1-5,59-61). The different prevalence of 
classic risk factors in the various territories are important for both predominance and 
prognosis: smoking is three times more likely to cause LEAD than coronary artery disease. 
(62) Conversely, the association of hypertension with LEAD is lower than the association of 
hypertension with coronary artery disease or cerebrovascular disease.(63). Indeed, patients 
with carotid atherosclerosis present a stronger relationship with arterial hypertension (and 
benefit more of antihypertensive treatment) than patients with coronary atherosclerosis.(64) 
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Multi-focal atherosclerosis in patients with LEAD as primary manifestation of disease 
 
Patients with LEAD  have a poor prognosis as this disease is associated with 2- to 6-fold 
risk of coronary and cerebrovascular disease, when compared to the normal population .(1-
5,65-73). In fact the presence of LEAD in itself  constitutes a very potent risk factor 
equivalent. The severity of LEAD goes hand in hand with an increased cardio- and 
cerebrovascular morbidity and mortality. Patients with more severe claudication present a 
higher prevalence of CAD and CVD than those with mild symptoms, and patients presenting 
with CLI, i.e. with rest pain or gangrene, will have the highest associated cardiovascular 
morbidity and mortality (up to 90%  incidence of CAD and 1-year mortality ranging from 
25% to 50%).(1-5,74) Cardiologists should better be aware of these figures while treating 
patients with  LEAD not only because of the deemed spontaneous prognosis but also when 
estimating the risk of a surgical intervention. The presence of LEAD stratify the patient into 
a higher risk group. One-third of patients with LEAD present coronary artery disease on the 
basis of history and electrocardiogram two-thirds on the basis of an abnormal stress test and 
up to 70% present at least single vessel disease at coronary angiography. Whether a silent 
concomitant CAD should be confirmed and treated by an invasive procedure depends at the 
end upon the cardiac indication to coronary angiography and revascularisation.(58).  
The risk of stroke in male patients with LEAD has been reported 4-5 times higher than in 
patients without LEAD. (73) Approximately 20% of patients with LEAD have a significant 
carotid stenosis detected at Duplex US ultrasound.(1-5,67,68). The severity of LEAD seems 
to  correlate with the severity of carotid artery stenosis (69). The presence of carotid bruits 
in LEAD patients should foster the search of carotid internal stenosis, i. e. by Duplex US: 
subsequent diagnostic and therapeutic strategies are driven again by the clinical 
presentation and the degree of the concomitant carotid stenosis. 
 
Multifocal involvement in patients presenting with carotid arteries atherosclerosis 
 
Patients with significant carotid artery disease (i.e. stenosis >70-80%) are more prone to die 
following acute coronary syndrome than cerebrovascular events, pointing to the high 
prevalence of concomitant coronary artery disease.(75) Thus, patients with carotid artery 
disease should undergo aggressive medical treatment of their risk factors in analogy to 
patients with “lone” coronary artery disease.  
Patients with symptomatic carotid artery atherosclerosis have per se a 30% and 20% co-
prevalence of CAD and LEAD respectively. (1-3,60) Recent studies indicate that patients 
with cerebrovascular atherosclerosis also have simultaneous subclinical LEAD as detected 
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by Duplex US and the ABI. (76,77) Whether and how a patient with significant carotid artery 
disease should be screened for the concomitancy of CAD remains a question of debate 
even in case of a planned invasive surgical carotid revascularization procedure(1-3). The 
bottom line remains that, in the presence of cerebrovascular atherosclerosis, the 
concomitant involvement of other territories is not infrequent, and in case of clinical 
suspicion should be actively searched by non-invasive methods. 
 
Patients presenting with aortic aneurysms as primary manifestation of disease  
 
It is well known that patients with aortic aneurysms present with higher prevalence of 
smoking, hypertension which are associated with diffuse atherosclerosis with high cardiac 
and vascular co-morbidities, i.e. coronary artery disease, heart failure, and carotid artery 
and/or LEAD. The presence of concomitant coronary atherosclerosis in patients undergoing 
abdominal (or thoracic) aneurysm repair has been extensively studied and its prevalence 
depends on the screening method (up to 50% according to the method of detection).(2,3,78) 
The high concomitant cardiovascular co-morbidity is a matter of major concern especially in 
patients needing open aortic repair  who have symptomatic coronary artery disease or 
decompensated heart failure (1-5,79). Conversely, in patients with stable coronary artery 
disease, the risk of cardiovascular events during aortic repair seems nowadays relatively 
low, obviating the need of preventive coronary revascularization.(58) 
 
Patients presenting with renal atherosclerosis 
 
Patients with unilateral and –most importantly – with bilateral renal artery atherosclerotic 
obstructions have a dismal prognosis because they probably represent a marker of the 
burden of global atherosclerosis.(41) Renal  function impairment in these cases seems to 
perpetuate and accelerate the process of systemic atherosclerosis which is associated in 
patients with chronic kidney disease with a cardiovascular mortality of 30-50%. 
(1,41,44,80) 
 
Comprehensive approach 
 
Given the broad spectrum of non-coronary atherosclerosis there is a need for a 
comprehensive approach. When facing a patient with non-coronary artery disease one has 
to keep in mind the frequent systemic feature of the disease, i.e. the potential involvement of 
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other territories, i.e. coronary or cerebrovascular arteries making the cardiologist a natural 
player in the management of these pathologies. This may especially be relevant not only for 
prognostic purposes but, most importantly, in cases where revascularisation is needed in 
order to plan and prioritize which territory should be firstly treated (concomitant or staged 
procedures). As recently underscored by the 2011 ESC guidelines on Peripheral Artery 
Diseases and by the NHLBI, a multidisciplinary team including specialists in cardiovascular 
medicine, vascular surgery, radiology and even sometimes other fields according to the 
organs involved should take care of these patients. Recently an EU division in vascular 
medicine has been officially recognized by the UE regulatory agency (UEMS)* in Europe, 
and a National Institute of Health (NIH) fellowship in clinical vascular medicine have been 
advocated in the US**. This speciality /fellowship includes a 2-3 year training period with 
intensive teaching in basic, clinical, pathophysiology, non-invasive and invasive diagnostic, 
prevention and therapeutic strategies in vascular medicine.  
Multidisciplinary boards, pending upon the local situation, may be more efficient when these 
organization models are integrated preferably into a broad cardiovascular concept, i.e. 
within cardiovascular centres. Major efforts in this direction should be pursued in order to 
better achieve a global management of patients with non-coronary and coronary 
atherosclerosis. 
 
*UEMS- European Union of Medical Specialists http://www.uems.net/EU –Division of 
Angiology 
 
** NHLBI Vascular Medicine Training Program Working Group 
Executive Summary http://www.nhlbi.nih.gov/Meetings/workshops/vascular-med.htm 
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Economical impact of non coronary atherosclerosis 
 
The results of REACH Registry - a large, international, prospective study of stable outpatient 
population with either established symptomatic atherothrombosis (CAD, cerebrovascular 
disease, or LEAD) - have clearly indicated that symptomatic LEAD is associated with the 
greatest costs when compared to coronary artery disease and cerebrovascular 
disease.(81,82) (Fig 4) In this registry the authors compared the rates of associated costs in 
the United States with LEAD across patient subgroups as well as the incidence of vascular-
related hospitalizations. Patients with symptomatic LEAD at enrolment were defined on the 
basis of presence of intermittent claudication with an ankle-brachial index (ABI)< 0.90 or a 
history of previous lower-limb revascularization (or amputation). Asymptomatic LEAD was 
defined when  ABI < 0.90 in the absence of symptoms. A total of 2396 (9.3%) had 
symptomatic and 213 (0.8%) had asymptomatic LEAD at baseline were considered for the 
cost analysis. Based on the results of the American REACH cohort and of the 2004 US 
census data, the total annual costs associated with vascular hospitalizations in patients with 
LEAD would excess $21 billion. Similar results and cost extrapolations have been observed 
in several European cohorts of the REACH Registry where two-year hospitalisation costs 
were highest for patients with LEAD. (83) These data emphasize the need for an early and 
aggressive identification, prevention and treatment of LEAD which is clearly under-
diagnosed and under-treated. Several further studies have underlined how LEAD is 
responsible of a major proportion of the burden on healthcare systems beyond from indirect 
costs, as  those related to lost productivity.(84) All these costs could potentially be reduced, 
i.e. through long-term prevention , when the disease would be recognized at an earlier 
stage- although such long-term prevention is expensive on its own.(85) Therefore there is a 
need for further prospective studies on cost-efficacy of long-term preventions strategies in 
the setting of non-coronary atherosclerosis, and in patients with LEAD which may allow to 
draw more solid cost-efficacy conclusions. The same holds also true in the field of cost–
benefit analysis of revascularization procedures in LEAD where there is also a need of 
prospective studies including long-term standardized evaluation of patient-centric results, 
and re-intervention outcomes as reported in a recent a systematic review of the Mayo clinic 
on economic evaluation of LEAD revascularization procedures. (86)  
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Areas of uncertainty 
 
Compared to CAD where a huge amount of prospective data based on RCTs has been 
generated during the last 3 decades on diagnostic-,preventive-, and therapeutic strategies, 
clinical research in non-coronary and multisite atherosclerosis - as reported in Table 3 and 4 
- has suffered of a relatively limited interest, and large RCTs are generally lacking. This may 
be related to the frequent involvement of multiple arterial districts preventing to focus in 
detail on each arterial area. Thus, several data on management of LEAD and on carotid 
artery disease are frequently extrapolated from results derived from CAD. Although the 
relevance of traditional risk factors has been evaluated in patients with LEAD, the role of 
emergent risk factors and of drug prevention has been limited studied in large prospective 
studies. We also have poor data on the causes of different behaviour in progression of 
atherosclerosis among the distinct arterial sites. 
Data regarding multisite atherosclerosis are lacking: the usefulness of carotid 
revascularization in asymptomatic patients with >80% internal carotid stenosis before CABG 
remains uncertain. The optimal timing (staged or synchronous), and the method for carotid 
revascularization ( carotid endarterectomy or stenting) in patients undergoing CABG have 
not yet been clearly identified.  
 
Conclusions 
 
Non-coronary atherosclerosis includes a large spectrum of disease with distinct 
manifestations at different vascular locations; it may occur in isolated form or-more frequently 
- simultaneously at various sites. Associated CAD is frequent especially in the case of lower 
limb atherosclerosis, which is a powerful predictor of mortality, hospitalizations, and costs. 
Awareness of the disease and active screening for non-coronary atherosclerosis using simple 
diagnostic tools are essentials for the detection of disease. Once diagnosed efforts should be 
made for a holistic management aiming at treating and preventing the whole spectrum of the 
disease and their complications.(2) 
This review by the ESC Working Group on Peripheral Circulation and by the panellists of  the 
2011 Zürich meeting suggest some tentative strategies (Table 3-5) in order to further improve 
management, and to increase visibility of non-coronary atherosclerosis. The panelists 
propose several tentative measures to be implemented in the field non coronary 
atherosclerosis , and to increase awareness of this disease complex.(Tables 4 and 5). The 
use of ABI as a diagnostic and prognostic tool should be more encouraged among GPs and 
specialists; females with LEAD should receive more attention; randomized clinical trials, 
15  
surveys, and registries on LEAD and multisite atherosclerosis should also be encouraged. 
Awareness of the disease should be increased  through public campaigns at european, 
national , and community levels. The medical communities should be sensitized trough the 
existing guidelines on peripheral arteries (1-5), and more emphasis on LEAD during 
graduate and postgraduate teaching.  
16  
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Table 1: Non-coronary atherosclerosis: Co-prevalence in other territories 
 
Affected Territory 
Carotid Arteries Aorta Renal Arteries 
Clinical 
Presentation 
  ICA <60% 
asymptomatic 
ICA >60% 
asymptomatic 
ICA >70% 
symptomatic 
Athero- 
embolism 
Thoracic aneurysm Abdominal 
aneurysm 
Hypertension 
or renal failure 
Associated 
Atherosclerosis 
CAD 
CVD 
PAD 
up to 25% 
 
up to 10% 
up to 35% 
 
up to 20% 
        >50% 
        >50% 
        >50% 
up to 40% 
up to 20% 
up to 30% 
>50% 
>50% 
>50% 
up to 90% 
up to 60% 
up to 60% 
 
CAD:coronary artery disease; CVD:cerebro-vascular disease; ICA: internal carotid artery stenosis; PAD: lower limb artery disease 
 
Co-prevalence estimated according: Circulation 2006;113:e463 e465; J Vasc Surg 2000;31:S1-S296; Eur Heart J 2011;32:2851-906 Adv Chronic Kidney Dis 2008;15:378-83; J Vasc 
Surg 1994;19:668-74 ; Circulation 2006;113:2623-2629 
 
 
Table 2: Lower limb artery disease: Co-prevalence in other territories 
 
Affected 
Territory 
Lower Limb Arteries 
Clinical 
Presentation 
Asymptomatic 
ABI <0.9 
Intermittent 
Claudication 
Acute limb ischemia Chronic critical limb ischemia Aneurysm 
 
Associated 
Atherosclerosis 
CAD 
CVD 
 
 
 
 
up to 50% 
up to 20% 
 
 
                                                                                   
AF frequent 
>50% 
 
 
up to 90% 
up to 60% 
 
 
 
up to 50% 
up to 20% 
 
ABI ankle brachial index; AF atrial fibrillation, CAD  coronary artery disease; CVD cerebrovascular disease;  
 
Co-prevalence estimated according: J Vasc Surg 1994;19:668-74 ; Eur Heart J 2011;32:2851-906; Circulation 2006;113:e463 e465;  
J Vasc Surg 2000;31:S1-S296; Eur Heart J 2011;32:2851-906 
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Table 3: Key messages by the panelists 
 
Key messages 
Prevalence of LEAD in subjects >60 years is higher than actually perceived by the medical community 
Prognosis in LEAD ( independent of symptoms)  is poor 
Multivascular atherosclerosis is frequent in the presence of  LEAD and is associated with high morbidity and mortality 
Patients with LEAD and multivascular disease receive insufficient primary and secondary prevention 
 
 
Table 4: Measures to be implemented in non-coronary atherosclerosis 
 
Measures to be implemented in non-coronary atherosclerosis 
Further increase awareness in the cardiology community and in the public of the clinical and prognostic relevance of LEAD  
Increase awareness of the importance of multi-vascular disease 
Females with LEAD should receive more attention 
The use of ABI as a diagnostic and prognostic tool should be encouraged among GPs and specialists 
RCTs and Surveys on LEAD and multisite atherosclerosis are needed 
 
 
Table 5: Measures to increase awareness for non-coronary atherosclerosis 
 
Targets Measures to increase awareness 
Public Public campaigns in analogy to NIH, VDF
*
 campaigns at European-national-, regional-community levels 
General Practioners Spread the message that LEAD and multi-vessel disease are more prevalent than actually perceived by the medical community 
Organize ABI courses 
Reimbursement for ABI measurement by GPs 
Cardiologists Enhance graduate and postgraduate teaching in non-coronary atherosclerosis 
Spread  existent Guidelines on LEAD 
Promote RCTs and survey on management of LEAD at European level 
Industry Involvement in public, GPs and specialists awareness and prevention campaigns 
 
 
* Vascular Diseases Foundation
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Legends to Figures 
 
Legend to Figure 1 
One-year cardiovascular event rates as a Function of number of symptomatic disease 
locations 
All P values <.001. CV indicates cardiovascular; MI, myocardial infarction. Patients with at least 3 
factors but no symptoms are counted as 0, even in the presence of asymptomatic carotid plaque or 
reduced ankle brachial index. Error bars represent 95% confidence intervals (JAMA. 2007;297:1197-
1206 adapted with permission by the author and the Publisher). 
 
Legend to Figure 2 
Hazard ratios for total mortality in men and women by ankle-brachial index at baseline for all studies 
combined in the ABI Collaboration. 
(Circulation 2012;126:2890-2909) 
 
Legend to Figure 3 
 
Estimated Prevalence of peripheral arterial disease in the European Union 
Estimation obtained through http://europa.eu.int/en/comm/eurostat/eurostat.html and estimation 
form GetABI study* (Circulation 2009;120:2053-61)** 
 
Legend to Figure 4 
 
Data from the One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in 
the United States (US REACH- Registry) Costs across patient subgroups defined according to 
specific arterial bed(s) affected and the number of affected arterial beds. Total costs per patient 
(mean, with 95% confidence interval) adjusted for covariates by presence of Multiple Risk Factors 
(MRFs) ONLY and number of diseased vascular (Vasc) beds (cerebrovascular, coronary and 
peripheral). Hosp indicates hospitalization; MRFs, multiple risk factors. There is a consistent increase 
in costs with each additional diseased arterial bed. 
Adapted from Circulation: Cardiovascular Quality and Outcomes. 2008;1:38-45. Permission of the 
Publisher required. 
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Figure 1: One-year cardiovascular event rates as a Function of  
number of symptomatic disease locations   
 
 
 
Figure 2 Hazard ratios for total mortality in men and women by 
ankle-brachial index at baseline for all studies     
combined in the ABI Collaboration 
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Figure 3 
 
 
 
 
 
 
Estimated prevalence of peripheral arterial 
disease in the European Union 
500,000,000 inhabitants* 
17.1% aged > 65 years* 
20% of patients aged > 65 years have PAD** 
 
*Eurostat, **getABI 
17,000,000 patients with PAD in EU 
 Figure 4:Non-coronary atherosclerosis: additional costs 
according to involvement of vascular beds 
 
 
